Take2 licenses Grail’s nasopharyngeal cancer detection platform
By Hongjiang Li, Staff Writer | May 8, 2019 | 8:52 PM GMT
Editor's Note: This article was updated on May 8, 2019 at 11:29 PM GMT
Grail Inc. (Menlo Park, Calif.) granted Take2 Health Ltd. (Hong Kong, China) exclusive, worldwide rights to a portfolio of technology for the early detection of nasopharyngeal cancer. Financial terms were not disclosed.
Read the full 335 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD